Compare Stocks: MIST, RLMD, AVIR, and SPRY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$5.17	$5.19	$2.78 ▼ $6.45	$414.69M	0.28	280,150 shs	280,667 shs
MIST Milestone Pharmaceuticals	$0.79	$1.09	$0.75 ▼ $3.06	$98.16M	0.98	1.46 million shs	1.26 million shs
RLMD Relmada Therapeutics	$3.83	$4.66	$1.62 ▼ $8.00	$408.55M	0.45	1.26 million shs	1.31 million shs
SPRY ARS Pharmaceuticals	$4.08	$5.45	$4.02 ▼ $13.15	$405.76M	1.05	1.41 million shs	1.03 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	-3.00%	-3.54%	+12.15%	+76.45%
MIST Milestone Pharmaceuticals	0.00%	-13.91%	-32.03%	-40.72%	-60.58%
RLMD Relmada Therapeutics	0.00%	-7.04%	-11.55%	-45.13%	+111.60%
SPRY ARS Pharmaceuticals	0.00%	-0.73%	-30.73%	-52.34%	-58.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$5.17	$5.19	$2.78 ▼ $6.45	$414.69M	0.28	280,150 shs	280,667 shs
MIST Milestone Pharmaceuticals	$0.79	$1.09	$0.75 ▼ $3.06	$98.16M	0.98	1.46 million shs	1.26 million shs
RLMD Relmada Therapeutics	$3.83	$4.66	$1.62 ▼ $8.00	$408.55M	0.45	1.26 million shs	1.31 million shs
SPRY ARS Pharmaceuticals	$4.08	$5.45	$4.02 ▼ $13.15	$405.76M	1.05	1.41 million shs	1.03 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	-3.00%	-3.54%	+12.15%	+76.45%
MIST Milestone Pharmaceuticals	0.00%	-13.91%	-32.03%	-40.72%	-60.58%
RLMD Relmada Therapeutics	0.00%	-7.04%	-11.55%	-45.13%	+111.60%
SPRY ARS Pharmaceuticals	0.00%	-0.73%	-30.73%	-52.34%	-58.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.33	Hold	$7.00	35.40% Upside
MIST Milestone Pharmaceuticals	2.71	Moderate Buy	$6.40	711.77% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	213.32% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$25.00	512.75% Upside

Current Analyst Ratings Breakdown

Latest MIST, RLMD, AVIR, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	RLMD Relmada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/8/2026	SPRY ARS Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
9/3/2026	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	MIST Milestone Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$3.00
8/17/2026	SPRY ARS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$6.00 ➝ $7.00
7/17/2026	AVIR Atea Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	MIST Milestone Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	MIST Milestone Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$3.53 per share	N/A
MIST Milestone Pharmaceuticals	$1.55M	63.33	N/A	N/A	$0.39 per share	2.02
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A
SPRY ARS Pharmaceuticals	$84.28M	4.81	N/A	N/A	$1.16 per share	3.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$158.35M	-$2.08	N/A	N/A	N/A	N/A	-64.25%	-57.12%	11/11/2026 (Estimated)
MIST Milestone Pharmaceuticals	-$63.06M	-$0.69	N/A	N/A	N/A	N/A	-288.33%	-58.27%	11/11/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-47.52%	-43.97%	11/12/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)

Latest MIST, RLMD, AVIR, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
8/12/2026	Q2 2026	AVIR Atea Pharmaceuticals	-$0.5550	-$0.41	+$0.1450	-$0.41	$33.03 million	N/A
8/12/2026	Q2 2026	MIST Milestone Pharmaceuticals	-$0.1950	-$0.21	-$0.0150	-$0.21	$0.82 million	$0.56 million
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	8.13	8.13
MIST Milestone Pharmaceuticals	3.25	8.13	7.92
RLMD Relmada Therapeutics	N/A	29.52	29.52
SPRY ARS Pharmaceuticals	13.72	3.48	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
MIST Milestone Pharmaceuticals	86.18%
RLMD Relmada Therapeutics	45.24%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	21.60%
MIST Milestone Pharmaceuticals	5.03%
RLMD Relmada Therapeutics	14.50%
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	55	80.21 million	62.88 million	Optionable
MIST Milestone Pharmaceuticals	38	124.50 million	118.24 million	Optionable
RLMD Relmada Therapeutics	17	106.67 million	91.20 million	Optionable
SPRY ARS Pharmaceuticals	200	99.45 million	65.83 million	Optionable

MIST, RLMD, AVIR, and SPRY Headlines

Recent News About These Companies

SPRY DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

4 hours ago | newsfilecorp.comN

Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action

4 hours ago | newsfilecorp.comN

SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

September 26 at 8:23 AM | globenewswire.com

SPRY DEADLINE: ROSEN, TRUSTED INVESTOR RIGHTS COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY

September 25 at 10:17 PM | globenewswire.com

SPRY DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

September 25 at 8:55 PM | newsfilecorp.comN

Robbins LLP Reminds SPRY Stockholders of the Pending October 5, 2026 Lead Plaintiff Deadline in ...

September 25 at 7:49 PM | gazettextra.comG

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026

September 25 at 7:49 PM | newmediawire.comN

Robbins LLP Reminds SPRY Stockholders of the Pending October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action Against ARS Pharmaceuticals Inc.

September 25 at 6:33 PM | globenewswire.com

Kaplan Fox Alerts Investors of ARS Pharmaceuticals Inc. (SPRY) to an Upcoming Deadline of October 5, 2026 in the Securities Class Action

September 25 at 3:15 PM | newsfilecorp.comN

Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Who Suffered Losses to a Securities Class Action – Deadline is October 5, 2026

September 25 at 9:45 AM | globenewswire.com

Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm Before Lead Plaintiff Deadline on October 5, 2026

September 24, 2026 | theglobeandmail.com

SPRY FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

September 24, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

September 24, 2026 | prnewswire.com

Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role

September 24, 2026 | globenewswire.com

Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of a Securities Class Action Lawsuit - Deadline is October 5, 2026

September 24, 2026 | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 24, 2026 | globenewswire.com

SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact SueWallSt

September 24, 2026 | prnewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

September 24, 2026 | globenewswire.com

SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

September 24, 2026 | prnewswire.com

Kaplan Fox Alerts Investors to an Upcoming Deadline of October 5, 2026 in the ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Securities Class Action

September 23, 2026 | theglobeandmail.com

ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 12-Month Low - Should You Sell?

September 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MIST, RLMD, AVIR, and SPRY Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$5.17 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$5.18 +0.00 (+0.10%)

As of 09/25/2026 07:30 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Milestone Pharmaceuticals NASDAQ:MIST

$0.79 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$0.79 +0.00 (+0.20%)

As of 09/25/2026 07:56 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Relmada Therapeutics NASDAQ:RLMD

$3.83 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$3.83 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

ARS Pharmaceuticals NASDAQ:SPRY

$4.08 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$4.05 -0.03 (-0.71%)

As of 09/25/2026 07:58 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MIST, RLMD, AVIR, and SPRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MIST, RLMD, AVIR, and SPRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MIST, RLMD, AVIR, and SPRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MIST, RLMD, AVIR, and SPRY Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

Milestone Pharmaceuticals NASDAQ:MIST

Relmada Therapeutics NASDAQ:RLMD

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MIST, RLMD, AVIR, and SPRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MIST, RLMD, AVIR, and SPRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MIST, RLMD, AVIR, and SPRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MIST, RLMD, AVIR, and SPRY Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

Milestone Pharmaceuticals NASDAQ:MIST

Relmada Therapeutics NASDAQ:RLMD

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools